세계의 재조합 DNA 기술 시장 규모 조사 및 예측 : 제품, 구성요소 유형, 용도, 최종 용도 및 지역별 분석(2023-2030년)

Global Recombinant DNA Technology Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Recombinant DNA Technology is a method primarily used to alter the phenotype of an organism (host) after introducing and integrating a genetically changed vector into the organism's genome. This procedure essentially entails the introduction of an unfamiliar piece of DNA structure into the genome that houses our gene of interest. Recombinant DNA technology is used to create newly developed recombinant genes. Recombinant DNA technology uses several techniques, equipment, and other particular procedures to produce artificial DNA in order to create the desired result. The rising government initiatives, rising emergence of recombinant insulin, surging demand for recombinant/ genetically modified products, coupled with the rising prevalence of chronic diseases are the most prominent factors that are propelling the market demand across the globe.

Additionally, the rapid expansion of the biopharmaceutical industry is playing a significant role in augmenting the global market expansion. Biopharmaceuticals are drugs that are produced using living organisms, and many of them are developed using recombinant DNA technology. According to Statista, in 2022, the biopharmaceuticals sector was estimated to account for USD 403.1 billion across the globe, which is projected to constantly rise and estimated to reach USD 974.5 billion by 2030. Also, the continuous progress of rDNA techniques has created novel opportunities for biopharmaceutical research by enabling the formation of a recombinant DNA molecule. The adoption of this technology is anticipated to be fueled by the presence of a strong biopharmaceuticals pipeline, particularly the pipeline for recombinant proteins. The expansion of this market is largely attributable to the development of recombinant products using rDNA techniques in conjunction with CRISPR/Cas9 nuclease, ZFN, and TALEN enabling simple & accurate genome editing with no constraints by organisms. Numerous review studies conducted by researchers have demonstrated the effectiveness of rDNA technology. Moreover, the technological advancements in genomics, as well as the rising R&D initiatives and strategic collaborations by market players presents various lucrative opportunities over the forecasting years. However, the risks associated with the use of genetically modified food and regulatory, scientific, and ethical challenges related with gene therapy are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Recombinant DNA Technology Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing number of biopharmaceutical manufacturing companies, along with growing research and development activities. For instance, in May 2022, PharmaJet announced that the National Institute on Ageing (NIA) branch of the National Institutes of Health (NIH) granted its partner, the Institute for Molecular Medicine (IMM), a USD 12 million award. The award funds the development of beta-amyloid vaccines based on recombinant proteins and DNA for the treatment and prevention of Alzheimer's disease (AD). Such studies are accelerating the market's expansion. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecasting years. The presence of low-cost manufacturing centers, rising awareness regarding the benefits of this technology, increasing patient pool, as well as rising investments by many government organizations are significantly propelling the market demand across the region.

Major market players included in this report are:

• F. Hoffmann-La Roche Ltd (Genentech, Inc)
• Profacgen
• Amgen Inc
• Novartis AG
• GenScript
• Pfizer Inc
• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi
• Merck & Co., Inc.

Recent Developments in the Market:

• In March 2022, VBI Vaccines Inc. unveiled the launch of PreHevbrio (Recombinant Hepatitis B Vaccine) for the treatment of individuals 18 years of age and older patients are at risk of contracting any of the identified subtypes of the hepatitis B virus (HBV).
• In February 2022, the 3-antigen hepatitis B (HBV) vaccine manufactured by VBI Vaccines Inc. under the trade name PreHevbri received approval from the European Medicines Agency's Committee for Medicinal Products for Human Use. This vaccine is intended to protect adults from an infection caused by a particular subtype of the hepatitis B virus.

Global Recombinant DNA Technology Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Product, Component Type, Application, End-use, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

• Medical
• Non-medical

By Component Type:

• Expression System
• Cloning Vector

By Application:

• Food & Agriculture
• Health & Disease
• Environment
• Others

By End-use:

• Pharmaceutical & Biotech Companies
• Academic & Research Institutes
• Other

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Recombinant DNA Technology Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Recombinant DNA Technology Market, by Product, 2020-2030 (USD Billion)
  • 1.2.3. Recombinant DNA Technology Market, by Component Type, 2020-2030 (USD Billion)
  • 1.2.4. Recombinant DNA Technology Market, by Application, 2020-2030 (USD Billion)
  • 1.2.5. Recombinant DNA Technology Market, by End-use, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Recombinant DNA Technology Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Recombinant DNA Technology Market Dynamics

• 3.1. Recombinant DNA Technology Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rapid expansion of the biopharmaceutical industry
    • 3.1.1.2. Surging demand for recombinant/ genetically modified products
  • 3.1.2. Market Challenges
    • 3.1.2.1. Risks associated with the use of genetically modified food
    • 3.1.2.2. Regulatory, scientific, and ethical challenges related with gene therapy
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Technological advancements in genomics
    • 3.1.3.2. Rising R&D initiatives and strategic collaborations by market players

Chapter 4. Global Recombinant DNA Technology Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Recombinant DNA Technology Market, by Product

• 5.1. Market Snapshot
• 5.2. Global Recombinant DNA Technology Market by Product, Performance - Potential Analysis
• 5.3. Global Recombinant DNA Technology Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
• 5.4. Recombinant DNA Technology Market, Sub Segment Analysis
  • 5.4.1. Medical
  • 5.4.2. Non-medical

Chapter 6. Global Recombinant DNA Technology Market, by Component Type

• 6.1. Market Snapshot
• 6.2. Global Recombinant DNA Technology Market by Component Type, Performance - Potential Analysis
• 6.3. Global Recombinant DNA Technology Market Estimates & Forecasts by Component Type 2020-2030 (USD Billion)
• 6.4. Recombinant DNA Technology Market, Sub Segment Analysis
  • 6.4.1. Expression System
  • 6.4.2. Cloning Vector

Chapter 7. Global Recombinant DNA Technology Market, by Application

• 7.1. Market Snapshot
• 7.2. Global Recombinant DNA Technology Market by Application, Performance - Potential Analysis
• 7.3. Global Recombinant DNA Technology Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 7.4. Recombinant DNA Technology Market, Sub Segment Analysis
  • 7.4.1. Food & Agriculture
  • 7.4.2. Health & Disease
  • 7.4.3. Environment
  • 7.4.4. Others

Chapter 8. Recombinant DNA Technology Market, by End-use

• 8.1. Market Snapshot
• 8.2. Global Recombinant DNA Technology Market by End-use, Performance - Potential Analysis
• 8.3. Global Recombinant DNA Technology Market Estimates & Forecasts by End-use 2020-2030 (USD Billion)
• 8.4. Recombinant DNA Technology Market, Sub Segment Analysis
  • 8.4.1. Pharmaceutical & Biotech Companies
  • 8.4.2. Academic & Research Institutes
  • 8.4.3. Others

Chapter 9. Global Recombinant DNA Technology Market, Regional Analysis

• 9.1. Top Leading Countries
• 9.2. Top Emerging Countries
• 9.3. Recombinant DNA Technology Market, Regional Market Snapshot
• 9.4. North America Recombinant DNA Technology Market
  • 9.4.1. U.S. Recombinant DNA Technology Market
    • 9.4.1.1. Product breakdown estimates & forecasts, 2020-2030
    • 9.4.1.2. Component Type breakdown estimates & forecasts, 2020-2030
    • 9.4.1.3. Application breakdown estimates & forecasts, 2020-2030
    • 9.4.1.4. End-use breakdown estimates & forecasts, 2020-2030
  • 9.4.2. Canada Recombinant DNA Technology Market
• 9.5. Europe Recombinant DNA Technology Market Snapshot
  • 9.5.1. U.K. Recombinant DNA Technology Market
  • 9.5.2. Germany Recombinant DNA Technology Market
  • 9.5.3. France Recombinant DNA Technology Market
  • 9.5.4. Spain Recombinant DNA Technology Market
  • 9.5.5. Italy Recombinant DNA Technology Market
  • 9.5.6. Rest of Europe Recombinant DNA Technology Market
• 9.6. Asia-Pacific Recombinant DNA Technology Market Snapshot
  • 9.6.1. China Recombinant DNA Technology Market
  • 9.6.2. India Recombinant DNA Technology Market
  • 9.6.3. Japan Recombinant DNA Technology Market
  • 9.6.4. Australia Recombinant DNA Technology Market
  • 9.6.5. South Korea Recombinant DNA Technology Market
  • 9.6.6. Rest of Asia Pacific Recombinant DNA Technology Market
• 9.7. Latin America Recombinant DNA Technology Market Snapshot
  • 9.7.1. Brazil Recombinant DNA Technology Market
  • 9.7.2. Mexico Recombinant DNA Technology Market
• 9.8. Middle East & Africa Recombinant DNA Technology Market
  • 9.8.1. Saudi Arabia Recombinant DNA Technology Market
  • 9.8.2. South Africa Recombinant DNA Technology Market
  • 9.8.3. Rest of Middle East & Africa Recombinant DNA Technology Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
  • 10.1.1. Company 1
  • 10.1.2. Company 2
  • 10.1.3. Company 3
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. F. Hoffmann-La Roche Ltd (Genentech, Inc)
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Recent Developments
  • 10.3.2. Profacgen
  • 10.3.3. Amgen Inc
  • 10.3.4. Novartis AG
  • 10.3.5. GenScript
  • 10.3.6. Pfizer Inc
  • 10.3.7. Novo Nordisk A/S
  • 10.3.8. Eli Lilly and Company
  • 10.3.9. Sanofi
  • 10.3.10. Merck & Co., Inc.

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes
• 11.3. Research Assumption